@article{6abe12007e224d848b27395ff1ade882,
title = "Rectally Administrated Thioguanine for Distal Ulcerative Colitis: A Multicenter Case Series",
keywords = "Inflammatory bowel disease, rectal thioguanine, ulcerative colitis",
author = "Femke Crouwel and Melek Simsek and {van Doorn}, {Amarylle S.} and Mulder, {Chris J. J.} and Buiter, {Hans J. C.} and Barclay, {Murray L.} and Florin, {Timothy H.} and {de Boer}, {Nanne K.}",
note = "Funding Information: F.C., A.vD., C.M., H.B., and M.B. have nothing to declare. M.S. has received an unrestricted research grant from TEVA. T.F. consults for Douglas Pharmaceuticals Pty Ltd, which is developing a distal intestine extended release formulation of thioguanine. N.dB. has served as a speaker for AbbVie and MSD and has served as consultant and principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted) research grant from Dr. Falk, TEVA Pharma BV, MLDS, and Takeda.",
year = "2023",
month = jun,
day = "1",
doi = "https://doi.org/10.1093/ibd/izac195",
language = "English",
volume = "29",
pages = "1000--1004",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "6",
}